90471 CPT Code: The Pediatric Guide to Vaccine Administration Billing

What is the 90471 CPT code?

The 90471 CPT code is the immunization administration code for giving one injectable vaccine by percutaneous, intradermal, subcutaneous, or intramuscular route. It pays for the act of administering the dose, not for the vaccine itself, so every claim also needs a separate vaccine product code. In pediatrics it applies when no provider counseling is documented, or when the patient is over 18.

• 90460 or 90471. Use 90460, plus +90461 for each additional component, for patients through age 18 when face-to-face provider counseling is documented. Reserve 90471 for patients over 18 or visits where the note shows no counseling.
• More than one injectable vaccine. Report 90471 once for the first injectable vaccine and +90472 for each additional one. Billing 90471 twice triggers a duplicate service edit.
• Not every shot is a 90471. RSV monoclonal antibodies use 96380 or 96381, COVID-19 vaccines use 90480 and +90481, and Medicare flu, pneumococcal, and hepatitis B doses use G0008, G0009, and G0010.

What does the 90471 CPT code cover?

CPT 90471 covers the administration of one injectable vaccine: preparing the dose, giving the injection, and the required record keeping. The American Medical Association defines it as immunization administration by percutaneous, intradermal, subcutaneous, or intramuscular injection for one vaccine, single or combination. It never includes the vaccine product, which is billed on its own line.

Every immunization claim has two moving parts, and 90471 is only one of them. The first part is the administration code, which tells the payer that a professional gave the shot. The second is the vaccine product code, which tells the payer exactly which vaccine was used, for example 90686 for a quadrivalent flu vaccine or 90715 for Tdap. Submitting 90471 without a matching product code reads as incomplete billing and usually comes back as a CO-16 missing information rejection. The reverse is also true: a product code with no administration code leaves the administration fee unpaid.

Route does not change the code inside the injectable family. Intramuscular, subcutaneous, intradermal, and percutaneous all report as 90471. A combination product still counts as one vaccine for administration purposes, which matters because the counseling codes handle combination products very differently, as the next section explains.

The most common issue we see providers run into is treating 90471 as the default for every shot rather than as one option inside a set of administration families. Once the wrong family is chosen, no amount of clean data entry downstream fixes the claim, and the denial usually comes back late enough that the timely filing window is already tight.

Should you bill 90460 or 90471?

Use 90460, plus +90461 for each additional component, for patients through age 18 when a physician or qualified health professional documents face-to-face counseling. Use 90471 and +90472 for patients over 18, or when the chart shows no counseling. Age and documented counseling are the only two variables that decide it.

The mechanics differ in a way that drives the dollars. The counseling codes are built around vaccine components, so a combination product that protects against several diseases can be reported per antigen. The non-counseling codes are built around each vaccine, not each component.

Consider a two-year-old at a well visit who receives four injectable vaccines with documented counseling, one of them a six-component combination product such as Vaxelis. Under the counseling set, the practice reports 90460 once for the first or only component of each vaccine and +90461 for each additional component, which comes to nine reported units. Under the non-counseling set, the same encounter collapses to 90471 plus +90472 three times, or four units. Same visit, same work, less than half the reported units.

The guardrail is documentation. To support 90460 and 90461, the note has to show face-to-face counseling about the risks, benefits, and side effects of the vaccines given, delivered by the physician or qualified health professional rather than by staff. If the chart only says vaccines administered, the encounter defaults to 90471 and 90472. Getting this right is less about coding knowledge than about a clean handoff between the exam room and the billing team, which is why the fix usually lives in the visit template rather than in the billing queue.

Does 90460 always pay more than 90471?

No. For commercial plans that price each component separately, 90460 and 90461 usually pay more than 90471 and 90472. Under Vaccines for Children, CMS caps the administration fee per vaccine rather than per component, and CDC guidance directs that 90461 be valued at zero for VFC-entitled children.

This is the part almost every 90471 article gets wrong, and it matters because VFC doses make up a large share of pediatric vaccine volume. On the Kentucky Medicaid preventive health fee schedule revised in April 2026, 90460 and 90471 carry the identical administration rate, $19.93 with the SL modifier for state-supplied vaccine and $27.49 otherwise, while 90472 pays $11.96. Arizona went further: AHCCCS closed 90461 for VFC administration effective October 1, 2024, and now pays a single flat rate per administration when 90460 is billed with the SL modifier.

So the component advantage is real on the commercial side and often nonexistent on the VFC side. A practice with a commercial-heavy panel that habitually defaults to 90471 is leaving money on the table. A practice with a Medicaid-heavy panel that spends staff time chasing the same fix may be optimizing something its fee schedule does not pay for.

Across the billing companies we vet, a recurring pattern separates the strong pediatric operators from the rest: they split the vaccine administration analysis by payer class before recommending a coding change, rather than applying one national rule to every claim. If you want to see how we vet pediatric billing companies, that payer-by-payer discipline is one of the things we screen for.

90471, 90472, 90473, and 90474 Compared

Once age and counseling point you to the non-counseling set, the specific code depends on the route and on whether the dose is the first or an additional vaccine at that visit. The table below breaks down the four core administration codes.

CPT Code	What it reports	Route	First or add-on
90471	Immunization administration, one vaccine	Injection (IM, SC, ID, percutaneous)	First injectable vaccine
90472	Each additional vaccine	Injection (IM, SC, ID, percutaneous)	Add-on, use with 90471
90473	Immunization administration, one vaccine	Oral or intranasal	First oral or intranasal vaccine
90474	Each additional vaccine	Oral or intranasal	Add-on, use with a primary code

Two rules trip practices up here. First, do not report 90473 alongside 90471 as two primary codes for the same encounter, since each is a first vaccine by a different route. When a child gets one injectable and one oral vaccine, report 90471 for the injection and +90474 for the oral dose. Second, 90472 and 90474 are add-on codes and cannot stand alone on a claim without a primary administration code.

Sequence also affects payment. Using Kentucky as the example again, 90471 pays $19.93 with the SL modifier while 90472 pays $11.96, so a claim that reports the add-on as the primary, or that omits the primary entirely, loses roughly 40 percent of the administration fee on that line before anyone notices.

Units are the other quiet failure point. Each additional vaccine gets its own unit of the add-on code, so a visit with four injectable vaccines reports 90471 once and 90472 three times, not 90472 with a quantity of three on a single line if the payer expects separate lines. Check the payer companion guide, because policies differ on whether units or separate lines adjudicate cleanly, and a mismatch shows up as a partial payment rather than a denial.

When 90471 Is the Wrong Code

Some of the most expensive vaccine billing errors are not coding mistakes inside the 90471 family at all. They happen when a product that is not a vaccine, or not a standard vaccine, gets pushed through the 90471 family anyway. These are the four boundaries that matter most in a pediatric office right now.

• RSV monoclonal antibodies. Nirsevimab and clesrovimab are monoclonal antibodies, not vaccines. Report administration with 96380 when a physician or qualified professional counsels on the same date, or 96381 when they do not. Do not use 90471 or 90472, and do not link Z23, since the correct diagnosis is Z29.11 for prophylactic immunotherapy against RSV. Our guide to RSV immunization billing for the 2026-2027 season walks through the product and administration pairs.
• COVID-19 vaccines. COVID-19 administration runs on 90480 for the first or only component of each vaccine, with +90481 added in 2026 for each additional component. The new influenza and COVID-19 combination products, 90612 and 90613, bill with 90480 and 90481 rather than the 90471 family.
• Medicare patients. For influenza, pneumococcal, and hepatitis B, Medicare requires G0008, G0009, and G0010 instead of 90471. CMS NCCI policy also instructs that administration families should not be mixed on a single date of service, which is where mixed or family practices see repeat denials.
• Nurse-only vaccine visits. CMS NCCI guidance states that 99211 is not separately reportable with vaccine administration codes. A nurse-only immunization visit is billed with the administration code and the product, not with a low-level office visit stacked on top.

Providers often come to us after a quarter of RSV or COVID-19 denials that nobody could explain, and the cause is almost always this: the product moved into a new code family and the charge capture template did not move with it.

How do you bill the 90471 CPT code correctly?

Billing 90471 cleanly is a short, repeatable checklist. Confirm the code family, report the primary once, add the correct add-on codes, pair every dose with its product code and diagnosis, and handle modifiers before the claim leaves the building. Run every immunization encounter through these eight steps.

• Confirm that no face-to-face counseling is documented, or that the patient is over 18.
• Report 90471 once for the first injectable vaccine administered that day.
• Add +90472 for each additional injectable vaccine given at the same visit.
• Bill the matching vaccine product code on its own line, for example 90686 for flu or 90715 for Tdap.
• Link ICD-10 Z23 to each administration and product line so the payer sees why the service was performed.
• Append modifier 25 to the E/M office visit when a separate, significant problem is addressed on the same day.
• Add the SL modifier on state-supplied VFC doses and report the vaccine product at zero dollars.
• Verify that the payer does not bundle administration into the preventive visit before billing 90471 separately.

Order matters on the claim. List 90471 ahead of its add-on codes, keep one unit per line rather than stacking units on a single 90471 line, and make sure each vaccine product line sits next to the administration line it belongs to. Payers that auto-adjudicate immunization claims read that structure literally, and a claim that reverses it can pay the add-on rate on the primary dose.

The documentation side is shorter than most teams expect. The note needs the vaccine given, the route, the site, the lot and expiration, the Vaccine Information Statement edition date and the date it was provided, and who administered the dose. If the encounter is being routed to 90471 specifically because counseling was not performed, the absence of counseling should be evident from the note rather than assumed by the biller.

What are the most common 90471 denials?

Most 90471 denials trace back to a short list of avoidable patterns: a missing vaccine product code, 90471 billed twice instead of 90471 plus 90472, a missing Z23 diagnosis, a payer that bundles administration into the preventive visit, or a VFC dose billed with the product charged. Each one is preventable with a claim-level check before submission.

• Missing vaccine product code. 90471 submitted alone reads as incomplete billing and returns a missing information rejection, often CO-16. Send the administration code and the product code together, every time.
• Duplicate 90471. Billing 90471 twice for two injectable vaccines triggers a duplicate service edit. The correct structure is 90471 once plus +90472 for each additional vaccine.
• Missing Z23. Without a diagnosis supporting the immunization encounter, the payer returns the claim for missing information. Z23 links to each administration and product line.
• Bundling into the preventive visit. Some commercial plans fold administration into the preventive visit payment, which produces a CO-97 when 90471 is billed separately. Check the policy before unbundling.
• VFC product billing error. For Vaccines for Children doses, bill the administration with the SL modifier and never charge for the vaccine product. Billing the product on a VFC dose is a compliance problem, not just a denial.
• Using 90471 when 90460 was supported. When counseling is documented for a patient through age 18, 90471 can underpay on commercial plans and flags as a documentation mismatch on audit.

One question we hear constantly from practice managers is why vaccine denials cluster in October and November. The answer is usually seasonal volume meeting a code set that changed in January and a charge capture template that was never updated to match.

What changed for 90471 in 2026, and what is coming in 2027?

The core 90471 rules did not change for 2026, but the codes around it did. Three time-based immunization counseling codes took effect on January 1, 2026, the COVID-19 administration descriptor was revised and gained an add-on, and the CY 2027 Medicare proposed rule would lower both conversion factors.

• New counseling-only codes. CPT 90482, 90483, and 90484 report immunization counseling on dates when no vaccine is administered, tiered by cumulative time of 3 to 10 minutes, more than 10 up to 20 minutes, and more than 20 minutes, with work RVUs of 0.24, 0.50, and 0.75. Only one may be reported per date of service, the primary diagnosis is Z71.85 followed by a Z28 code, and modifier 25 goes on the E/M. CMS assigned them status indicator I, so they are not payable under Medicare, and commercial and Medicaid coverage varies. The AMA detailed them in the March 2026 CPT Assistant.
• Time cannot be counted twice. Counseling time already captured by 90460, 90461, 90471 through 90474, 90480, 90481, 96380, or 96381 cannot be counted again toward 90482 through 90484.
• COVID-19 administration. The 90480 descriptor was revised for 2026 to cover the first or only component of each vaccine administered, and +90481 is new for each additional component.
• 2026 Medicare values. CMS set two CY 2026 conversion factors, $33.4009 for nonqualifying APM participants and $33.5675 for qualifying participants. At 0.66 total RVUs, 90471 calculates to roughly $22.04 nationally in the office setting, before geographic adjustment.
• 2027 proposed cuts. CMS released the CY 2027 proposed rule on July 14, 2026, with proposed conversion factors of $32.84 and $33.17 as the temporary 2.5 percent increase expires. At the proposed nonqualifying rate and current RVUs, the national 90471 calculation would land near $21.68.

One 2027 proposal deserves a closer read than it usually gets. CMS has proposed paying only the highest-valued service at 100 percent when a separately identifiable office or outpatient E/M visit is furnished on the same day as a procedure carrying a 0, 10, or 90 day global period. Vaccine administration codes including 90471 carry an XXX global indicator, meaning the global concept does not apply, so as written the proposal would not sweep in modifier 25 on a routine immunization visit. That is worth confirming in the final rule rather than assuming, and our breakdown of the 2027 Medicare payment changes for pediatrics tracks where it lands.

Coverage churn is the other 2026 variable. Schedule changes move which doses are payable and which need prior authorization, and payer policies have not moved in lockstep. Our coverage of the 2026 vaccine schedule changes and the AAP 2026 vaccine guidance and coverage gaps covers what to verify before the claim goes out.

Frequently Asked Questions